Close Menu

NEW YORK – Quanterix said on Wednesday afternoon that it has commenced an underwritten public offering of $75 million of shares of its common stock.

In connection with the stock offering, Quanterix intends to grant underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock at the public offering price.

JP Morgan Securities and SVB Leerink are acting as joint book-running managers for the offering. Cannacord Genuity is acting as co-manager for the offering.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.

Resistance to ash dieback disease among some UK ash trees appears polygenic, the Independent reports.

In Nucleic Acids Research this week: sequencing strategy for flash-frozen brain tissue bank samples, new version of ChlamDB, and more.

A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.